Project research

Our research program has been focused on studying the regulation of brain lipid composition and metabolism by ApoE isoforms in Alzheimer’s Disease (AD) pathogenesis. Recent evidence from my lab uncovers novel roles for reducing a brain PIP2 degrading enzyme synaptojanin 1 expression in AD therapies. One of our current research projects is to develop preclinical candidates and new chemical scaffolds targeted at its expression. More importantly, we will investigate mechanistic actions of newly developed drug candidates in AD which will shed lights on understanding pathways underlying ApoE-associated AD pathogenesis.

In parallel, another major lab focus is to understand the mechanisms underlying ApoE4-associated impairment in phospholipid homeostasis and AD development. We recently characterized a novel regulatory role of a microRNA, miR-195 in the ApoE4-PIP2-synj1 pathway. Our current effort is to further evaluate therapeutic and diagnostic implications of miR-195 in AD.

Other projects in the lab are focusing on exploring the interaction between ApoE4 and other risk factors such as traumatic brain injury and female sex in AD development and progression, as well as protective roles of ApoE2 against aging and AD. We also work on investigating the role of ApoE isoforms in injury models such as spinal cord injury.